5 completed, 2 unknown, 2 withdrawn. 9 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Unknown 2, Withdrawn 2 |
| Phase 2 | 1 | Unknown 1 |
Follow Tegafur: new trials by email Literature Review of Tegafur trials Research Report on Tegafur
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 RO7496353, Atezolizumab, Capecitabine - Non-small Cell Lung Cancer, Gastric Cancer | Phase 1 | Completed | Genentech, Inc. | 102 | 2023-10-02 | 2026-06-18 |
| CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer Tegafur, Gimeracil and Oteracil Potassium Capsules (one drug) - Cervical Cancer, Chemotherapy | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 200 | 2020-04-15 | 2020-03-19 |
| Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers Oxaliplatin, Albumin-Bound Paclitaxel /nab-Paclitaxel, S-1 - Gastric Cancer in Situ, Pancreatic Cancers | Phase 1 | Completed | National Health Research Institutes, Taiwan | 18 | 2018-06-26 | 2022-04-07 |
| Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC HCC antigens-specific CD8+ T lymphocytes, IL-2, Tegafur - Hepatocellular Carcinoma | Phase 1 | Unknown | Beijing YouAn Hospital | 18 | 2017-05-01 | 2018-01-18 |
| Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC iNKT cells, IL-2, Tegafur - Hepatocellular Carcinoma | Phase 1 | Completed | Beijing YouAn Hospital | 10 | 2017-04-01 | 2024-09-19 |
| Combination Chemotherapy in Treating Patients With Advanced Solid Tumors etoposide, leucovorin calcium, tegafur-uracil - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Withdrawn | University of Pittsburgh | 1999-12-01 | 2013-12-19 | |
| Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors leucovorin calcium, paclitaxel, tegafur-uracil - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Withdrawn | University of Pittsburgh | 1999-12-01 | 2013-12-19 | |
| Combination Chemotherapy In Treating Patients With Advanced Cancer gemcitabine hydrochloride, leucovorin calcium, tegafur-uracil - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Barbara Ann Karmanos Cancer Institute | 36 | 1998-05-01 | 2013-04-08 |
| Combination Chemotherapy and Radiation Therapy in Treating Patients With Colorectal Cancer leucovorin calcium, tegafur-uracil, radiation therapy - Colorectal Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 30 | 1996-04-01 | 2013-12-19 |
Carcinoma, Hepatocellular (2) · Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Pancreatic Neoplasms (1) · Rectal Neoplasms (1) · Stomach Neoplasms (1) · Uterine Cervical Neoplasms (1)
Beijing YouAn Hospital (2) · University of Pittsburgh (2) · Barbara Ann Karmanos Cancer Institute (1) · Genentech, Inc. (1) · Memorial Sloan Kettering Cancer Center (1) · National Health Research Institutes, Taiwan (1) · Peking Union Medical College Hospital (1)
United States (3) · China (2) · Australia (1) · Brazil (1) · Italy (1) · Japan (1) · New Zealand (1) · South Korea (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1)
Chandra P. Belani, MD (2) · Bruce D. Minsky, MD (1) · Jun Lu, Director (1) · Ke Hu, MD (1) · Li-Tzong Chen, MD PHD (1) · Philip A. Philip, MD, PhD, FRCP (1)
PMID 10442378, PMID 17414457, PMID 38902994
P30CA022453 (1)